Insider trades by month
US insider trades, September 2023
The 9,845 open-market buys and sales by US company CEOs, executives and directors filed in September 2023.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Netsol TechnologiesNTWK | Open-market buy | 23/09/29 | 23/09/29 | 8,907 sh | $1.94 | $17,279.58 | +1.1% | |
Neumora TherapeuticsNMRA | Open-market buy | 23/09/28–23/09/29 | 23/09/29 | 76,511 sh3 trades | $13.68avg. | $1,046,848.16 | +2.0% | |
Neumora TherapeuticsNMRA | Open-market buy | 23/09/28–23/09/29 | 23/09/29 | 76,511 sh3 trades | $13.68avg. | $1,046,848.16 | +2.0% | |
Neumora TherapeuticsNMRA | Open-market buy | 23/09/28–23/09/29 | 23/09/29 | 76,511 sh3 trades | $13.68avg. | $1,046,848.16 | +2.0% | |
Kurt Von EmsterDirector | CymaBay Therapeutics | Open-market sale10b5-1 plan | 23/09/29 | 23/09/29 | 15,921 sh | $15.68 | $249,641.28 | −15.0% |
Ronald E. Toupin Jr.Director | Guggenheim Active Allocation FundGUG | Open-market buy | 23/09/29 | 23/09/29 | 215 sh | $13.54 | $2,911.1 | +2.3% |
Randall C. BarnesDirector | Guggenheim Active Allocation FundGUG | Open-market buy | 23/09/29 | 23/09/29 | 1,784 sh | $13.58 | $24,226.72 | +7.0% |
Farmland PartnersFPI | Open-market buy | 23/09/27–23/09/29 | 23/09/29 | 100,000 sh3 trades | $10.26avg. | $1,026,130.96 | +8.3% | |
Scott B. UllemCVP, CFO | Edwards LifesciencesEW | Open-market sale10b5-1 plan | 23/09/29 | 23/09/29 | 7,255 sh | $69.54 | $504,512.7 | −27.4% |
Thomas K. EquelsCEO & President | AIM ImmunoTechAIM | Open-market buy | 23/09/29 | 23/09/29 | 22,676 sh | $0.44 | $9,977.44 | +3.9% |
Sharp Laura IngleDirector | Ingles MarketsIMKTA | Open-market sale | 23/09/29 | 23/09/29 | 2,000 sh | $75.05 | $150,100 | −4.5% |
Neumora TherapeuticsNMRA | Open-market buy | 23/09/28–23/09/29 | 23/09/29 | 76,511 sh3 trades | $13.68avg. | $1,046,848.16 | +2.0% | |
Anthony S. ClarkDirector | Taiwan FundTWN | Open-market buy | 23/09/29 | 23/09/29 | 1,000 sh | $30.07 | $30,070 | +100.0% |
CFO | NateraNTRA | Open-market sale | 23/09/28–23/09/29 | 23/09/29 | 2,291 sh2 trades | $45.92avg. | $105,193.14 | −3.4% |
William C. WernerEVP, Strategy & Development | BJ's Wholesale Club HoldingsBJ | Open-market sale10b5-1 plan | 23/09/29 | 23/09/29 | 890 sh | $72.47 | $64,498.3 | −2.9% |
Voip-pal.comVPLM | Open-market sale | 23/09/25–23/09/29 | 23/09/29 | 400,000 sh5 trades | $0.02avg. | $8,000 | −27.4% | |
MongoDBMDB | Open-market sale10b5-1 plan | 23/09/27–23/09/29 | 23/09/29 | 616 sh2 trades | $339.66avg. | $209,230.56 | −1.8% | |
Susan G. KimSEE REMARKS | Pacific Biosciences of CaliforniaPACB | Open-market sale | 23/09/29 | 23/09/29 | 19,257 sh | $8.44 | $162,529.08 | −5.9% |
Neumora TherapeuticsNMRA | Open-market buy | 23/09/28–23/09/29 | 23/09/29 | 76,511 sh3 trades | $13.68avg. | $1,046,848.16 | +2.0% | |
Cantaloupe | Open-market buy | 23/09/27–23/09/29 | 23/09/29 | 16,696 sh3 trades | $6.31avg. | $105,322.64 | +12.2% |
Other months
- September 20262,604
- June 202620,298
- May 202614,504
- April 20269,432
- March 202614,721
- February 202610,638
- January 20267,844
- December 202512,093
- November 202511,751
- October 202513,072
- September 202513,090
- August 202514,381
- July 20258,748
- June 202511,426
- May 202511,415
- April 20256,792
- March 202512,399
- February 202510,686
- January 20258,151
- December 202416,069
- November 202416,983
- October 20248,518
- September 202410,511
- August 202414,013
- July 202410,847
- June 202412,704
- May 202412,649
- April 20248,608
- March 202417,622
- February 202413,916
- January 20249,748
- December 202314,239
- November 202312,685
- October 20236,365
- September 20239,845
- August 202312,892
- July 20237,232
- June 202311,204
- May 202313,009
- April 20235,870
- March 202313,084
- February 202311,300
- January 20238,626